Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$17.98 - $25.47 $36,876 - $52,238
-2,051 Reduced 2.37%
84,660 $2.07 Million
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $218,133 - $292,539
-12,401 Reduced 12.51%
86,711 $1.85 Million
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $1.38 Million - $2.11 Million
99,112 New
99,112 $1.9 Million
Q3 2021

Nov 15, 2021

SELL
$29.97 - $36.66 $4.49 Million - $5.49 Million
-149,831 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$25.39 - $32.61 $888,548 - $1.14 Million
-34,996 Reduced 18.93%
149,831 $4.58 Million
Q1 2021

May 17, 2021

BUY
$19.92 - $31.6 $819,668 - $1.3 Million
41,148 Added 28.64%
184,827 $5.63 Million
Q4 2020

Feb 16, 2021

SELL
$12.16 - $19.77 $1.41 Million - $2.29 Million
-116,060 Reduced 44.68%
143,679 $2.84 Million
Q3 2020

Nov 16, 2020

SELL
$11.25 - $14.75 $2.78 Million - $3.65 Million
-247,131 Reduced 48.76%
259,739 $3.39 Million
Q2 2020

Aug 14, 2020

BUY
$10.69 - $16.49 $5.1 Million - $7.86 Million
476,653 Added 1577.43%
506,870 $5.75 Million
Q1 2020

May 15, 2020

BUY
$9.78 - $29.53 $295,522 - $892,308
30,217 New
30,217 $432,000
Q1 2019

May 15, 2019

SELL
$26.93 - $34.7 $646,939 - $833,598
-24,023 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $1.75 Million - $2.92 Million
-64,198 Reduced 72.77%
24,023 $698,000
Q3 2018

Nov 14, 2018

BUY
$37.57 - $50.34 $4,921 - $6,594
131 Added 0.15%
88,221 $4.06 Million
Q2 2018

Aug 14, 2018

BUY
$27.75 - $40.17 $2.44 Million - $3.54 Million
88,090 New
88,090 $3.29 Million
Q1 2018

May 15, 2018

SELL
$28.83 - $41.01 $1.06 Million - $1.51 Million
-36,710 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$28.45 - $37.14 $1.04 Million - $1.36 Million
36,710
36,710 $1.26 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.